LEADER 04358nam 22005295 450 001 9910337956603321 005 20200707001536.0 010 $a3-030-12668-4 024 7 $a10.1007/978-3-030-12668-1 035 $a(CKB)4930000000042022 035 $a(MiAaPQ)EBC5741975 035 $a(DE-He213)978-3-030-12668-1 035 $a(PPN)23522880X 035 $a(EXLCZ)994930000000042022 100 $a20190327d2019 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aReviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders /$fedited by Paul C. Guest 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (309 pages) 225 1 $aProteomics, Metabolomics, Interactomics and Systems Biology,$x2730-6216 ;$v1134 311 $a3-030-12667-6 327 $a1. Insulin Resistance in Schizophrenia -- 2. Biogenesis of the Insulin Secretory Granule in Health and Disease -- 3. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions -- 4. Preclinical Models of Altered Early Life Nutrition and Development of Reproductive Disorders in Female Offspring -- 5. Targeting Mitochondrial Defects to Increase Lngevity in Animal Models of Neurodegenerative Diseases -- 6. Computational Approaches for Identification of Pleiotropic Biomarker Profiles in Psychiatry -- 7. MiRNA Regulation of Glucose and Lipid Metabolism in Relation to Diabetes and Non-Alcoholic Fatty Liver Disease -- 8. Hypercaloric Diet-Induced Obesity and Obesity-Related Metabolic Disorders in Experimental Models -- 9. Metabolic Biomarkers in Nematode C. elegans During Aging -- 10. Circular RNAs as potential biomarkers and therapeutic targets for metabolic diseases -- 11. Deciphering Endothelial Dysfunction in the HIV-Infected Population -- 12. The Role of Inflammation in the Development of GDM and The Use of Markers of Inflammation in GDM Screening -- 13. PFKP Signaling at a Glance: an Emerging Mediator of Cancer Cell Metabolism -- 14. ATAD3A on the Path to Cancer -- 15. Impact of Exercise on Inflammatory Mediators of Metabolic and Vascular Insulin Resistance in Type 2 Diabetes. 330 $aThe book recognizes that throughout the scientific, medical, and economic communities, new tests incorporating biomarkers are needed to improve the diagnosis of patients suffering from metabolic disorders. The early identification of those at risk of developing obesity will help to place these individuals on the best treatment course as early as possible for improved treatment outcomes. This will also help to cut costs incurred by the healthcare services. For all of this to occur, new research efforts are needed to identify novel biomarkers that can be used to predict the disease in the presymptomatic stage, for disease monitoring and for prediction of treatment response. It is also possible that new drug targets can be identified using these approaches which, in turn, can lead to the development of new treatment approaches. This volume also includes a series of reviews on biomarker discovery and usage in the study of diseases marked by perturbations in metabolism. It will describe the pros and cons of the various approaches and cover the successes and failures in this important research field. 410 0$aProteomics, Metabolomics, Interactomics and Systems Biology,$x2730-6216 ;$v1134 606 $aProteomics 606 $aMedical genetics 606 $aDiabetes 606 $aProteomics$3https://scigraph.springernature.com/ontologies/product-market-codes/L1403X 606 $aGene Function$3https://scigraph.springernature.com/ontologies/product-market-codes/B12030 606 $aDiabetes$3https://scigraph.springernature.com/ontologies/product-market-codes/H33045 615 0$aProteomics. 615 0$aMedical genetics. 615 0$aDiabetes. 615 14$aProteomics. 615 24$aGene Function. 615 24$aDiabetes. 676 $a610.28 702 $aGuest$b Paul C$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910337956603321 996 $aReviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders$92280548 997 $aUNINA